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INTRODUCTION
Statins represent potent inhibitors of cholesterol bio-
synthesis, as they inhibit 3-hydroxy-3-methylglutaryl 
coenzyme A reductase, the rate limiting enzyme in 
this biosynthetic pathway. Consequently, statins are 
well established as first-line therapy for decreasing 
cardiovascular morbidity and mortality in patients with 
and without coronary disease. Due to its lipid-lower-
ing effects they are also used in the treatment of di-
abetes-associated hyperlipidemia. However, there are 
some concerns, coming from the growing experimen-
tal and clinical research of statins in diabetes, about the 
effect of statins on glucose metabolism and glycemic 
control. Some reports indicate an adverse [1, 2] or no 
effect of statins on insulin sensitivity [3, 4] while others 
reported a beneficial effect [5, 6]. Similar discrepancies 
exist in findings related to the effect of statins on β-cell 
mass/function, the second pathological hallmark of the 
diabetic state. For example, Urbano et al. [7] has found 
that atorvastatin impairs mitochondrial function in hu-
man pancreatic islet and rat β-cells in vitro. In contrast, 
recently published in vivo studies showed that statins 
improved islet function in streptozotocin-induced di-
abetes and obesity acting through anti-inflammatory 
and proliferative pathways in β-cells [8, 9]. The wide 
insight into literature data suggests that the effect of 
statins on glucose metabolism and insulin sensitivity 
depends on the type, dose and duration of statin treat-
ment as well as the model system (in vitro or in vivo) 
[10–12]. 
The special focus in diabetes treatment nowadays 
is to restore β-cell population (mass) and consequently 
their function. The neogenesis of β-cells from endo-
crine and exocrine non-insulin producing progenitors 
gave some promising results in the treatment of ex-
perimentally induced diabetes. Several stimuli/condi-
tions have been shown to induce pancreatic potency 
to regenerate β-cells, including gastrin and epidermal 
growth factor, extendin-4, duct ligation etc. [13–16]. 
Data from our previous study extended this list with 
L-arginine [17]. Namely, we observed that L-argi-
nine-NO producing pathway induces β-cell neogenesis
in alloxan-induced diabetes acting through the com-
plex transcriptional regulation of β-cell mass/function.
In the light of such conflicting data regarding sta-
tin effects in diabetes, we aimed to examine whether 
statins affect β-cell regeneration in diabetic pancre-
as. Accordingly, the localization/expression of insulin, 
along with specific insulin-related and proliferative 
transcription factors including pancreas duodenum 
homeobox-1 (PDX-1) and proliferating cell nuclear anti-
gen (PCNA), was examined in the pancreas of rats with 
alloxan-induced diabetes after 12–day treatment with 
simvastatin. 
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MATERIALS AND METHODS
Animals and diabetes induction
The experiments were approved by the Ethical Com-
mittee for the Treatment of Experimental Animals of 
the Institute for Biological Research ‘Siniša Stankov-
ić’, Belgrade. Male Mill Hill hybrid hooded, 3-month-
old rats (Rattus norvegicus, Berkenhout, 1769) were 
used. They were divided into two groups: diabetic and 
non-diabetic rats. Alloxan (Sigma, Germany) was ap-
plied to induce diabetes. After a 12 h fasting period, 
animals received a single alloxan dose of 120 mg/(kg 
body weight) i.p. Rats with blood glucose level ≥ 12 
mmol/L, measured by glucose oxidase reagent strips 
(GlucoSure test, “Prizma”, Kragujevac, Serbia) were 
considered diabetic. Both diabetic and non-diabetic 
groups were additionally separated in two subgroups. 
One subgroup was treated with simvastatin (5 mg/kg/
day) through gastric gavage, for 12 days. The second 
subgroup received intragastric infusion of saline and 
served as a control. Treatment of diabetic rats started 
after diabetes induction. The rats were maintained in 
individual cages with food and water ad libitum. Each 
experimental group consisted of six animals. After 12 
days of treatment, blood glucose level was determined 
and the rats killed by decapitation. The pancreas was 
dissected out within 3 min and thoroughly rinsed with 
physiological saline to remove traces of blood.
Biochemical tests
Blood was collected, allowed to clot and centrifuged 
(3500 g) to prepare serum. Serum insulin levels were es-
timated by radioimmunoassay (INEP, Belgrade, Serbia). 
Serum total and HDL (high-density lipoprotein)-cho-
lesterol as well as triglyceride levels were determined 
by an autoanalyzer (Spectrum CCx, Abbott, Chicago,IL, 
USA). LDL (low-density lipoprotein)-cholesterol was 
calculated from measured values of total cholesterol, 
triglyceride and HDL-cholesterol according to the Frie-
dewald calculation [18].
Student’s t test was used to evaluate significance of 
the differences. Statistical significance was accepted at 
P <0.05.
Immunohistochemistry
Immediately after dissection and washing, samples 
of pancreatic tissue were fixed in 10% formaldehyde 
at 4 °C overnight and processed routinely for embed-
ding in paraffin. 5 μm-thick serial pancreatic sections 
were deparaffinized and rehydrated. Immunoreactivity 
was assessed by the avidin-biotin-peroxidase method 
(following the manufacturer’s instructions; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). The sections were 
incubated with 3% H2O2 in methanol for 10 min at am-
bient temperature to block endogenous peroxidase, 
followed by three 5 min washes in 0.015 mol/L phos-
phate-buffered saline (PBS; pH 7.4) and incubated with 
1.5% normal goat serum (ABC Staining System, Santa 
Cruz Biotechnology) in PBS for 60 min at ambient tem-
perature to block non-specific sites. Primary antibod-
ies used in this study were anti-PDX-1 (1:1000; Abcam, 
Cambridge, UK) and anti-PCNA (1:200; Santa Cruz Bio-
technology, Santa Cruz, CA, USA). The sections were 
incubated with the primary antibody in PBS overnight 
at 4 °C, followed by two 5 min PBS washes, incubated 
with 1:200 IgG biotinylated serum goat anti-rabbit (ABC 
Staining System, Santa Cruz Biotechnology) in PBS for 
60 min at ambient temperature, followed by two 5 min 
PBS washes. After that, AB reagent (ABC Staining Sys-
tem, Santa Cruz Biotechnology) was added for 30 min 
at ambient temperature, followed by three 5 min PBS 
washes and incubation with 0.02% H2O2 and 0.075% 
diaminobenzidine (Sigma) in 0.05 mol/L Tris buffer, pH 
7.6, for 10 min in a dark room. Rinsing in distilled water 
and counterstaining with hematoxylin completed the 
experimental schedule. 
Insulin and PDX-1 were detected by confocal mi-
croscopy. Insulin was detected with anti-insulin anti-
body (1:1000; Abcam) in combination with fluorescein 
isothiocyanate (FITC)-conjugated secondary antibody 
(1:200; Abcam). For PDX-1 staining, the slides were 
incubated with anti-PDX-1 antibody (1:600; Abcam) 
followed by incubation with Alexa Fluor 568-labelled 
secondary antibodies (1:2000; Invitrogen, Paisley, UK). 
Confocal images were acquired with a Carl Zeiss confo-
cal laser scanning microscope LSM510 and a Windows 
NT operating system. The examination of fluorescent 
immunolabelled samples was performed under Ar la-
ser lamp (FITC+Alexa Fluor 568 double-stained sam-
ples were excited with 488 nm and 543 nm light, re-
spectively).
The specificity of the immune reaction, for both 
immunofluorescence and routine immunohistochem-
istry, was tested by replacing the primary antibody 
with a non-immune rabbit serum or by incubating the 
sections with the secondary antibody alone.
RESULTS
Metabolic data
As it is obvious from Figure 1A, there are no significant 
differences in blood glucose level in non-diabetic an-
imals, control and simvastatin-treated, between two 
time points: 1) before treatment (beginning of the ex-
periment) and 2) after 12–days of treatment (end of 
the experiment). Three time points were represented 
for glucose level in untreated and simvastatin-treated 
diabetic animals: 1) before diabetes induction; 2) at the 
beginning of diabetic state and/or treatment; 3) 12–
days after diabetes induction and/or treatment with 
simvastatin (Figure 1B). Level of blood glucose was 
significantly decreased after 12–days treatment of di-
abetic animals with simvastatin (point 3) compared to 
the value detected in those animals before treatment 
(point 2). 
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Figure 2 summarizes the changes of serum insulin, 
total, HDL-, LDL-cholesterol and triglyceride levels in 
non-diabetic and diabetic animals. In contrast to the 
trend for normalization of glucose after simvastatin 
treatment of diabetic animals, serum insulin level was 
significantly decreased in those animals compared to 
control, showing similar value as in untreated diabe-
tes (Figure 2A). Interestingly, total and LDL cholesterol 
were significantly increased in both simvastatin-treated 
groups, non-diabetic and diabetic, compared to con-
trol (Figure 2B). Furthermore, LDL cholesterol was high-
er in simvastatin-treated diabetic animals in relation to 
non-treated diabetic ones. In contrast, diabetic animals 
treated with simvastatin showed lower triglyceride lev-
els compared to both control and untreated diabetic 
animals. 
Localization/expression of insulin
As expected, insulin immunopositive areas were signifi-
cantly decreased in pancreas of diabetic animals (Figure 
3B) compared to controls (Figure 3A). Simvastatin tre-
atment of both non-diabetic and diabetic animals did 
Figure 1. Changes of blood glucose in non-diabetic 
and diabetic rats. Blood glucose levels in non-diabetic 
animals, control and simvastatin-treated, are present-
ed for two time points: 1) before treatment (beginning 
of experiment) and 2) after 12–days of treatment (end 
of experiment) (A). Glucose levels in untreated and 
simvastatin-treated diabetic animals are presented for 
three time points: 1) before diabetes induction; 2) at 
the beginning of diabetic state and/or treatment; 3) 
12–days after diabetes induction and/or treatment 
with simvastatin (B). The values represent the mean ± 
S.E.M of six animals per group. *Compared with value 
at time point 1, ***p < 0.001; # compared with value at 
time point 2, # #p < 0.01. 
Figure 2. Serum insulin and cholesterols/triglyceride 
levels in non-diabetic and diabetic rats at the end of 
experiment (A and B, respectively). Bars represent the 
mean ± S.E.M of six animals per group. *Compared to 
control, *p < 0.05, **p < 0.01, ***p < 0.001; # compared 
to diabetes, # # #p < 0.001.
Figure 3. Localization of insulin immunofluorescence 
in pancreas of control (A), diabetes (B), simvastatin (C) 
and diabetes + simvastatin (D) animals. Pancreas sec-
tions were double-labelled with anti-insulin antibody, 
and fluorescence analyzed by confocal microscope. In-
sulin staining appears as green fluorescence. Scale bar, 
20 μm.
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not significantly affect the pattern of insulin immuno-
positivity observed in the appropriate untreated group 
(control and diabetic, respectively) but significantly re-
duced insulin-positive signal in both groups, indicating 
suppression of insulin synthesis or additional secretion.
Localization/expression of PDX-1 and PCNA
The results of immunohistochemical staining of PDX-1 
are shown on Figure 4. Simvastatin significantly incre-
ased the number of immunopositive nuclei as well as 
cytoplasmic immunopositivity in pancreas of diabetic 
animals in relation to non-treated diabetic animals. 
Cytoplasmic immunopositivity is especially strong in 
tissue of non-diabetic animals treated with simvastatin 
compared to control. 
Figure 5 shows immunopositivity of PCNA in exam-
ined conditions. The number of immunopositive nu-
clei was increased after simvastatin treatment of both 
non-diabetic and diabetic animals compared to control 
and non-treated diabetic animals, respectively. Besides, 
there was strong immunopositivity in pancreatic cyto-
plasm of simvastatin-treated diabetic animals. 
DISCUSSION
Growing experimental and clinical research of statins 
in diabetes clearly suggests cholesterol-independent 
effects of this drug in this widespread metabolic dis-
ease. The results of the present study extended the 
knowledge on the effect of statins in diabetic pancre-
atic tissue. We have shown in this study that 12–day 
treatment with simvastatin did not restore insulin level 
in the serum and population of insulin-positive β-cells 
in the pancreas of diabetic animals. Furthermore, sim-
vastatin treatment of both non-diabetic and diabetic 
animals, did not significantly affect the pattern of in-
sulin immunopositivity observed in the appropriate 
untreated group (control and diabetic, respectively), 
but significantly reduced insulin-positive signal in both 
groups. The observed results suggest that short-term 
treatment with statins has no potential to induce β-cell 
regeneration. 
Wide usage of statins for the treatment of lipid me-
tabolism disturbances of various etiologies opens an 
important issue about the safety of their use related 
to glycemic control and glucose metabolism. The main 
concerns come from clinical studies mainly showing 
increased risk of development of diabetes type 2 in 
the subject using statins [19, 20]. However, data from 
basic molecular studies are inconsistent. Some of them 
speak in favor beneficial effects of statins on insulin re-
sistance and β-cells, other reported negative impact 
of statin therapy while some showed no effects. In 
the study presented herein simvastatin reduced insu-
lin-positive signal of both non-diabetic and diabetic 
animals.
PDX-1 has been described as an important tran-
scription factor that determines endocrine and be-
ta-cell destiny [21–24]. Manipulation of this transcrip-
tion factor and its signaling pathways has become the 
dominant approach for β-cell regeneration and non-β 
to β-cells reprograming in states where the function 
of the endocrine pancreas is compromised, including 
diabetes. We have shown that the L-arginine-NO pro-
ducing pathway induces activation (nuclear localiza-
tion) of PDX-1 in the diabetic pancreas [17]. Besides, 
the increased colocalization of this transcription factor 
with insulin in endocrine and especially exocrine pan-
creatic tissue, clearly suggests that L-arginine induces 
β-cell regeneration in diabetic pancreas through trans-
differentiation of exocrine into endocrine cells. 
Comparison of these results with the results of oth-
er in vivo studies examining effects of statins on β-cell 
Figure 4. Immunohistochemical staining for PDX-1 in 
pancreas of control (A), diabetes (B), simvastatin (C), 
diabetes + simvastatin (D) animals. Numerous nuclei 
with strong PDX-1 staining can be seen in endocrine 
and exocrine pancreas of simvastatin-treated diabetic 
group (D). Scale bars, 20 μm.
Figure 5. Immunohistochemical staining for PCNA in 
pancreas of control (A), diabetes (B), simvastatin (C), 
diabetes + simvastatin (D) animals. Simvastatin treat-
ment induced strong cytoplasmic and nuclear immu-
nopositivity in diabetic pancreas (D). Scale bars, 20 μm.
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function establishes the notion that the effect of these 
drugs will depend on the dose and duration of their 
application. In the present study simvastatin was ad-
ministrated in a dose of 5 mg/kg body weight for 12 
days. Li et al. [9] have found increases in islet function 
and proliferation in streptozotocin-induced diabetes 
after simvastatin treatment in a dose of 3 mg/kg/day 
but the duration of the treatment was much longer, 
lasting for 8 weeks. Similar results were found in obese 
mice treated with atorvastatin with higher dose (30 
mg/kg/day) and longer treatment (58 days) [8]. 
Interestingly, although there is no increase in β-cell 
population after simvastatin treatment, nuclear local-
ization of PDX-1 and PCNA was significantly increased 
in pancreas of treated animals. The activation of PDX-1 
and PCNA in both endocrine and exocrine tissues, has 
been previously correlated by others [25, 26] and our-
selves [10] with proliferation and regeneration of pan-
creatic islet. So, it seems likely that simvastatin adminis-
trated in the present schedule (time, dose) recruits the 
transcriptional program for β-cell regeneration without 
achieving the complete process. 
Considering the absence of normalization of serum 
insulin level by simvastatin, we were surprised that this 
drug counteracted hyperglycemia in diabetic animals. 
We suggest the possibility that restitution of hypergly-
cemia by simvastatin results from the peripheral mech-
anisms operating in regulation of plasma glucose level 
but not from the direct effect of the drug on the pan-
creatic tissue. There are growing data from in vitro and 
in vivo studies speaking in favor our hypothesis. The 
beneficial effect of statins, including simvastatin [27], 
on insulin sensitivity have been reported in diabetic 
patients and animal models of obesity and diabetes. 
For example, Wong et al. [28] reported that atorvasta-
tin increased glucose uptake in skeletal muscle leading 
to improved insulin sensitivity in Zucker lean and fatty 
rats, while Lalli et al. [29] described molecular mech-
anisms of improved insulin signaling in the liver and 
skeletal muscle in rats fed a high-fat diet. 
However, simvastatin did not normalize total cho-
lesterol level in diabetic rats and even increased LDL 
cholesterol. Such an unexpected outcome of statin 
treatment over cholesterol level and inhibition of its 
synthesis is not an isolated case reported for statin ad-
ministration in rats. For example, Ness et al. [30] have 
found that lovastatin increased HMG-CoA reductase 
activity in rat liver. Furthermore, Isusi et al. [31] have 
shown that there are differences in the capacity of var-
ious types of statins on cholesterol metabolism in liver, 
while simvastatin has been described as less effective 
in reduction of cholesterol ester synthesis. Besides, rats 
have low cholesterol levels that are generally unaffect-
ed by statins [32]. 
According the data from this study we conclude 
that short-term simvastatin treatment does not im-
prove diabetes-induced decrease in β-cell mass/func-
tion and/or induces β-cell regeneration. These data are 
in accordance with growing evidence that question ex-
clusively beneficial effects of statin administration and 
could be important for defining appropriate clinical 
use and schedule of statin treatment in non-diabetic 
and diabetic associated metabolic disturbances.
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Efekat simvastatina u pankreasu dijabetičnih pacova
Kratak sadržaj
Sve je više dokaza da statini ostvaruju holesterol-nezavisne efekte u dijabe-
tesu, ali ne postoji saglasnost da li su oni pozitivni ili negativni. U pokušaju 
da pojasnimo ovaj problem, ispitivali smo efekat simvastatina na regene-
raciju β-ćelija u dijabetesu. Dijabetes je indukovan kod mužjaka Mill Hill 
pacova jednom dozom aloksana (120 mg/kg). I nedijabetične i dijabetične 
životinje su podeljene u dve podgrupe: tretirane simvastatinom (5 mg/kg/
dan, i.g., 12 dana) i kontrolne. Tretman dijabetičnih životinja započelo je 
nakon indukcije dijabetesa (nivo glukoze ≥ 12 mmol/L). Naši rezultati po-
kazuju da nema povećanja površine insulin-imunopositivnih ćelija niti nor-
malizacije nivoa insulina u serumu nakon tretmana dijabetičnih životinja 
simvastatinom, iako je simvastatin povećao nukleusnu imunopozitivnost 
pankreasnog PDX-1 (engl. pancreas duodenum homeobox-1) i PCNA (engl. 
proliferating cell nuclear antigen). Rezultati studije pokazuju da 12-dnevni 
tretman simvastatinom nije poboljšao dijabetesom indukovane promene u 
masi i funkciji β-ćelija.
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